Novel gene-targeted epigenome therapy for unmet medical needs in CNS disorders
Learn MoreCLAIRIgene: intercepting gene expression to halt CNS diseases
Platform
All-in-one AAV or Lenti system for efficient expression modulation
Lead program, CLRI-002, potential to be First-in-Class Alzheimer’s Therapeutic
Platform technology with neurodegeneration programs and broad applications in gene therapy manufacturing
People
Industry-Validation: Partnered with Seelos Therapeutics for PD therapeutic
Partnership Duke Viral Vector Core and the Duke Translational Brain Sciences, Dept. of Neurology
Management with expertise in neurodegenerative diseases, gene therapy, and venture creation
Funding
~$400K in STTR Phase 1 from National Institute of Aging to develop AD therapeutic. Additional STTR from NCATS
Research funding from the Michael J. Fox Foundation for Parkinson’s Research
Research well-funded by NIH and Industry-sponsored research
Our story
CLAIRIgene, LLC was founded in 2019 as a spinout from Duke University to address the genetic causes of neurodegenerative diseases. Its primary technology is based on a research collaboration between Drs. Ornit Chiba-Falek and Boris Kantor. Dr. Chiba-Falek is Division Chief of Translational Brain Sciences at Duke University. Her research attempts to better understand the genetic processes underpinning age-related neurodegenerative diseases, in particular AD and Lewy body spectrum diseases. Dr. Kantor of the Duke University Viral Vector Core specializes in development of virus mediated tools for gene transfer
Founded by innovative scientists with decades of experience, CLAIRIgene is committed to rapidly advancing our therapeutics to the clinic. Our team has witnessed first-hand the turbulent journey those with dementia experience. Driven by science and inspired by dementia community, our team continues their dedication bring drugs to patients and work towards a better tomorrow for patients and their loved ones.
Ken Hamm, Alzheimer’s patient (1947-2020)